So why is Zavante brushing the dust off fosfomycin? After all, it was actually first tested in the 1960s in Spain, but had been ruled as fairly ineffective in comparison to other antibiotics on the market.
Zavante Therapeutics' antibiotic is scheduled to enter clinical trials next quarter, with aims to treat complicated urinary tract infections.
In an interview, Kyan Health Co-Founder and Chief Commercial Officer Konstantin Struck discussed how Kyan gives mid-market and enterprise employers access to premium workforce mental healthcare, at a price point that is affordable.